BiotechTube
AccuStem Sciences

AccuStem Sciences

London, United Kingdom· Est.
accustem.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $10.5M

Overview

AccuStem Sciences is a UK-based, clinical-stage diagnostics company developing innovative genomic tools for cancer detection and treatment guidance. The company is advancing its StemPrintER platform and expanding into blood-based testing through partnerships. Led by an experienced management team with deep oncology diagnostics expertise, AccuStem is positioning itself to address the growing need for precision oncology solutions, though it faces the typical risks of an early-stage company in a competitive and capital-intensive sector.

Oncology

Technology Platform

Genomic testing platform focused on cancer stem cell biology for prognostic stratification and detection, including the StemPrintER assay and developing blood-based liquid biopsy capabilities.

Funding History

2
Total raised:$10.5M
Series A$8M
Seed$2.5M

Opportunities

The global shift towards precision oncology and earlier cancer detection creates a large market for novel diagnostic tools.
Successfully validating its StemPrintER test could address an unmet need in breast cancer prognosis, while expansion into liquid biopsy positions the company in a high-growth segment for monitoring and treatment selection.

Risk Factors

Key risks include failure to demonstrate clinical utility and secure reimbursement for its tests, intense competition from larger, well-funded diagnostics companies, and reliance on external financing as a pre-revenue entity.
The shared CFO model may also present an operational risk.

Competitive Landscape

AccuStem operates in the highly competitive oncology diagnostics market, competing against established genomic test providers like Exact Sciences (Oncotype DX), Agendia (MammaPrint), and Myriad Genetics, as well as numerous liquid biopsy companies such as Guardant Health, Freenome, and Natera. Differentiation will require clear demonstration of superior clinical value.

More companies in Diagnostics & Precision Medicine →More companies in United Kingdom →